Nuvalent, Inc. (NUVL)
Automate Your Wheel Strategy on NUVL
With Tiblio's Option Bot, you can configure your own wheel strategy including NUVL - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol NUVL
- Rev/Share 0.0
- Book/Share 14.1194
- PB 5.2948
- Debt/Equity 0.0
- CurrentRatio 14.4808
- ROIC -0.3135
- MktCap 5368422524.0
- FreeCF/Share -2.846
- PFCF -26.3419
- PE -17.7938
- Debt/Assets 0.0
- DivYield 0
- ROE -0.3135
- Rating C-
- Score 1
- Recommendation Strong Sell
- P/E Score 1
- DCF Score 3
- P/B Score 1
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | NUVL | UBS | Neutral | Buy | -- | $100 | March 14, 2025 |
| Initiation | NUVL | H.C. Wainwright | -- | Buy | -- | $110 | Dec. 30, 2024 |
| Initiation | NUVL | Barclays | -- | Overweight | -- | $100 | Aug. 29, 2024 |
News
Nuvalent Outlines Recent Pipeline and Business Progress, Reiterates Key Anticipated Milestones, and Reports First Quarter 2025 Financial Results
Published: May 08, 2025 by: PRNewsWire
Sentiment: Neutral
Topline pivotal data expected for zidesamtinib in TKI pre-treated ROS1-positive NSCLC population in the first half of 2025 in support of anticipated first NDA submission by mid-year 2025 Initiation of ALKAZAR Phase 3 randomized, controlled trial of neladalkib for front-line ALK-positive NSCLC planned for first half of 2025 Pivotal data for neladalkib in TKI pre-treated ALK-positive NSCLC population anticipated by year-end 2025 Strengthened leadership team with key internal promotions CAMBRIDGE, Mass. , May 8, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today outlined …
Read More
Nuvalent Announces Publication in Molecular Cancer Therapeutics Reinforcing Rational Molecular Design of Zidesamtinib as a Novel ROS1-Selective Inhibitor
Published: April 29, 2025 by: PRNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass. , April 29, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the publication of a manuscript in Molecular Cancer Therapeutics, a journal of the American Association for Cancer Research, which supports the rational molecular design of zidesamtinib, its novel and selective ROS1 inhibitor.
Read More
Nuvalent to Participate in Upcoming March Investor Conferences
Published: February 28, 2025 by: PRNewsWire
Sentiment: Neutral
CAMBRIDGE, Mass. , Feb. 28, 2025 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced that James Porter, Ph.D.
Read More
About Nuvalent, Inc. (NUVL)
- IPO Date 2021-07-29
- Website https://www.nuvalent.com
- Industry Biotechnology
- CEO Dr. James R. Porter Ph.D.
- Employees 162